Navigation Links
Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
Date:7/11/2012

TARRYTOWN, N.Y., July 11, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2012 financial and operating results on Wednesday, July 25, 2012, before the U.S. financial markets open.  The Company will host a conference call at 8:30 AM EDT that day.

Live audio of the conference call will be webcast online simultaneously.  A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at www.regeneron.com.  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.  

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, EYLEA® (aflibercept) Injection and ARCALYST® (rilonacept) Injection for Subcutaneous Use.  Regeneron has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for EYLEA and ARCALYST and for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.

Contact Information:Manisha Narasimhan, Ph.D. 

Peter DworkinInvestor RelationsCorporate Communications914-847-512914.847.764Manisha.narasimhan@regeneron.competer.dworkin@regeneron.com


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron Announces June 2012 Investor Conference Presentations
2. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
3. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
4. China Pharmaceuticals and Healthcare Report Q3 2012
5. Questcor to Report Second Quarter Results on July 24, 2012
6. CareFusion To Report Fourth Quarter And Fiscal 2012 Results On Aug. 9
7. India Pharmaceuticals and Healthcare Report Q3 2012
8. Par Pharmaceutical Companies to Report Second Quarter 2012 Results on August 2, 2012
9. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
10. Draeger Welcomes NIOSH Investigation Report
11. Clinical Chemistry Market Report & Forecast (2012 - 2015): Global Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... CLEVELAND , Jan. 19, 2017 ViewRay, ... (DFG), a federal institution supporting research in ... installation and patient treatments at the University Clinic Heidelberg ... The MRIdian Linac program will be headed ... who also heads radiation oncology at the German Cancer ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017   Science ... is excited to announce that the first five ... Biology  (RP:CB) have been published in eLife today. ... project represents the first practical evaluation of reproducibility ... in reproducible studies. Unlike other assessments of reproducibility, ...
(Date:1/19/2017)... -- New Review of Safinamide - ... and Motor Complications in Mid- to Late-stage Parkinson,s ... ... C Warren Olanow , ... 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late Published recently ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Bill Howe Plumbing, Heating ... the American Heart Association; “Howe” Healthy is Your Heart Drawing Contest The ... active. Each year, Bill Howe Plumbing, Heating & Air receives over 600 entries. The ...
(Date:1/19/2017)... Marriottsville, MD (PRWEB) , ... January 19, 2017 , ... ... launched six new clients into the US market. , Over the past 20 years ... the past 4 weeks SFI has launched six new clients into the US market. ...
(Date:1/19/2017)... Georgia (PRWEB) , ... January 19, 2017 , ... ... Surgeons hosts the Atlanta Breast Surgery Symposium, a conference where hundreds of surgeons ... advancements in breast surgery. Covering topics from cosmetic breast augmentation to ...
(Date:1/18/2017)... ... 2017 , ... A recent video posting of a new fidget product gathered ... fidgeting to relieve stress and anxiety. No one was more surprised than Think ... just completed a successful Kickstarter campaign raising $67,000 on the popular crowdfunding platform. ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... manage it from the number one doctor-recommended OTC antiperspirant, Certain Dri. , Excessive ... go untreated. , Certain Dri created this infographic to explain the seven types ...
Breaking Medicine News(10 mins):